Blue Light and Milk
TO THE EDITOR: I am an enthusiastic reader of "On Being a Doctor," which is usually the first section I turn to in Annals. These essays have consistently described experiences and insights that were interesting, original, and thought provoking. My disappointment in the essay "Blue Light and Milk" (1) was therefore acute. This memoir struck me as sentimental and self-indulgent and the language as both trite and pretentious. I Fruit and Vegetable Intake and Coronary Heart Disease TO THE EDITOR: Joshipura and colleagues (1) presented epidemiologic evidence suggesting that consumption of green leafy vegetables and vitamin C-rich fruits and vegetables protects against coronary artery disease. The cardioprotective effect of green leafy vegetables may be due to high levels of the antioxidant lutein. In a recent experiment using epidemiologic data, an in vitro model, and a mouse model, Dwyer and coworkers (2) showed that lutein, a carotenoid with no pro-vitamin A activity, protected against progression of arteriosclerosis. Lutein achieved this effect by lowering very low-density lipoprotein and intermediate-density lipoprotein levels via pathways that reduced inflammation and oxidative stress in the arterial wall. In a 1996 study comparing the plasma concentrations of antioxidant vitamins and carotenoids in two populations, Howard and associates (3) showed that lutein played a potential role in the prevention of coronary disease. In that study, the major difference in antioxidant status between the two populations was in the plasma concentration of lutein, which was approximately twofold higher in the population with lower incidence of coronary disease. Increased intake of green leafy vegetables also protects against age-related macular degeneration, the leading cause of irreversible blindness in persons older than 65 years of age in developed countries (4) . Since arteriosclerosis is a risk factor for age-related macular degeneration, the widely recognized role of lutein in the prevention of the latter disorder must be at least partially related to its prevention of arteriosclerosis. 4 
TO THE EDITOR:
We read with interest the study by Joshipura and colleagues (1) , which reported that the consumption of one additional daily serving of fruit or vegetables (beyond the median level of consumption) was associated with a 4% reduction in coronary events. Relative terms often do not give a good sense of the benefit of interventions. Increasingly, there is a call for the use of absolute numbers, such as the number needed to treat for benefit (NNT B ), as a way of addressing the "clinical bottom line" when interpreting the results of clinical studies (2) . In applying this concept to the study by Joshipura and colleagues, we recognized that the NNT B may not adequately convey the magnitude of the behavioral change required to prevent one event. As an alternative, we propose a new term, the number needed to eat for benefit, or NNE B .
We calculate the NNE B in the following manner: In the Nurses' Health Study (3), the annualized rate of coronary events was 0.096% (1127 events in 84 251 women over 14 years). A 4% reduction in this rate would yield an absolute risk reduction of 0.004%, which can be translated into a NNT B of 25 000 (that is, 25 000 women like the women in this study would need to eat an extra daily portion of fruit or vegetables to prevent one coronary event over 1 year). Multiplying the NNT B over 1 year by 365 portions per year gives us a NNE B of 9 125 000. In other words, the women in this study would need to consume 9 125 000 more portions of fruit or vegetables to prevent a single coronary event. We estimate that the NNE B for the men in the Health Professionals' Follow-Up Study (4) would be 2 807 580 portions.
The NNE B may be a useful measure for giving practitioners and patients a better sense of the impact of dietary changes. We suggest that authors consider using it in reports on the association between diet and clinical outcomes. The suggestion by Drs. Alves-Rodrigues and Thomas that the cardioprotective effect of green leafy vegetables may be related to high lutein levels is based on an animal study of lutein and arteriosclerosis (1) and a study among humans examining the relation between lutein and other antioxidants and coronary disease (2) . In our study, we mentioned that antioxidant vitamins, folate, fiber, and such minerals as potassium may contribute to the apparent beneficial effects of fruits and vegetables, and we agree that lutein may also partly explain this benefit.
Peter Lindenauer, MD, MSc
Dr. Lindenauer and colleagues propose a new term, NNE B , as a better alternative to relative risk or to NNT B . We estimated that for one person in our study sample to avoid a coronary event, 1443 persons would have to increase consumption of fruits and vegetables by one serving per day for 12 years. Lindenauer and colleagues suggest that the NNT B may not adequately convey the magnitude of the behavioral change required to prevent one event. However, the NNE B is more difficult to interpret because it does not include information on number of participants and time. Also, as we mentioned in our study, any estimates like these are largely dependent on characteristics of the study sample and can be very misleading (for example, they could easily vary 50-fold depending on age distribution). Furthermore, it is important to differentiate between implications for drug trials and implications for fruits and vegetables, which are unlikely to have side effects and are beneficial for many diseases.
Questioning the Treatment of Venous Thromboembolism

TO THE EDITOR:
In their review of clinical trials that have influenced the treatment of venous thromboembolism (1), Drs. Hirsh and Bates omitted a crucial study by Nielsen and colleagues (2) . The Nielsen study compared anticoagulation with heparin plus phenprocoumon and therapy with phenylbutazone in patients with deep venous thrombosis (DVT). The results of the study were negative: One of 48 patients who received anticoagulants and 0 of 42 patients who received phenylbutazone died of pulmonary embolism. The only other previously published randomized, controlled trials of anticoagulants versus placebo in DVT also showed no benefit with anticoagulation (3, 4).
Heparin and vitamin K antagonists became standard treatment for DVT and pulmonary embolism in the 1940s, before randomized, controlled trials were routinely used to prove efficacy. The U.S. Food and Drug Administration (FDA) allowed these therapies to be "grandfathered in" in the early 1960s, when proof of efficacy became required for FDA approval. Low-molecular-weight heparins have been granted indications for treatment of DVT because randomized, controlled trials have shown their effects to be equivalent to those of heparin in trials that did not use "unanticoagulated" controls.
Drs. Hirsh and Bates referenced a randomized trial by Barritt and Jordan (5) comparing anticoagulants with placebo in patients with pulmonary embolism. That trial should not be used as a basis for medical treatment policy. Its flaws include a small number of patients (n ϭ 35), clinical diagnosis without lung scans or angiograms, 10 days of prescribed complete bed rest, and questionable determinations of deaths from pulmonary embolism.
David K. Cundiff Kailua-Kona, HI 96740
IN RESPONSE: Our article discussed clinical trials that have influenced practice. The study by Barritt and Jordan (1) did so and was of historical importance. Barritt and Jordan found that in patients who were considered to have pulmonary embolism, 5 of 19 who did not receive anticoagulants died compared with 0 of 16 who did. This difference was statistically significant (P ϭ 0.036). Several subsequent randomized trials (2-4) have supported Barritt and Jordan's contention that anticoagulants are indicated to treat patients with venous thromboembolism.
The study by Nielsen and colleagues (5) is interesting but did not influence practice. The authors themselves stated, "[T]he patient population. . . is relatively small with wide confidence intervals for differences between groups. Before more general recommendations can be made, a large-scale placebo-controlled study is needed to evaluate the possible effect of [anticoagulant] treatment in DVT patients who can be mobilized from the first day." It should also be noted that the relative risk for progression of proximal venous thrombosis in this study was almost 40% greater in phenylbutazonetreated patients than in anticoagulant-treated patients.
RESEARCH LETTERS
Rapid-Onset Type 1 Diabetes Mellitus without Pancreatic Exocrine Dysfunction
TO THE EDITOR: Imagawa and coworkers (1, 2) proposed a nonautoimmune fulminant subtype of type 1 diabetes mellitus characterized by the absence of insulitis and diabetes-related antibodies, rapid-onset elevated levels of serum pancreatic enzyme at diagnosis, and lymphocytic infiltration of the exocrine pancreas. However, pancreatic exocrine dysfunction may suggest an autoimmune rather than a nonautoimmune response in this subtype (3, 4) .
We examined the pancreatic biopsy specimen of a 50-year-old Japanese man with rapid-onset type 1 diabetes mellitus. He was admitted to our hospital with diabetic ketoacidosis 3 days after rapidonset symptoms of hyperglycemia. His blood glucose concentration was 26.3 mmol/L (474 mg/dL), and his glycosylated hemoglobin level was 0.061 (6.1%). Six days before admission, these values had been 3.9 mmol/L (70 mg/dL) and 0.054 (5.4%), respectively. Serum pancreatic enzyme levels were normal, and there were no diabetesrelated antibodies. The patient's HLA-DRB1, DQA1, and DQB1 genotypes were *0405/*0410, *0303/*0303, and *0401/*0402. No significantly elevated titers of antiviral antibodies, including rotavirus, were detected.
Histopathologic examination of a biopsy specimen obtained at the 33rd day after the patient's admission showed absence of insulitis and cell infiltration in the exocrine pancreas ( Figure, panels A and B) . The islets contained a majority of ␣-cells and a minor population of ⌬-cells, but no ␤-cells ( Figure, panels C 
through E). No CD3
ϩ T lymphocytes were evident in the islets and the exocrine pancreas (Figure, panel F) .
Although our patient is very similar to the patients described by Imagawa and colleagues (1, 2), he did not have pancreatic exocrine dysfunction. Therefore, we believe that no autoimmune response was involved in the pathogenesis and that our case might be classified as unadulterated nonautoimmune fulminant type 1 diabetes mellitus rather than as a variant form of the subtype proposed by Imagawa and colleagues (1, 2) .
Masatoshi Yamazaki, MD, PhD Tatsuhiko Hayashi, MD, PhD
Murakami General Hospital Murakami 958-8533, Japan
Hepatotoxicity after Prophylaxis with a Nevirapine-Containing Antiretroviral Regimen TO THE EDITOR: Postexposure prophylaxis is recommended after high-risk occupational HIV exposure in health care workers (1) . Some regimens include non-nucleoside reverse transcriptase inhibitors because these agents have favorable pharmacokinetics and dosing schedules and have successfully prevented mother-to-child HIV transmission (2) . The use of nevirapine, a non-nucleoside reverse transcriptase inhibitor, is complicated by 1% rates of hepatotoxicity and the Stephens-Johnson syndrome in HIV-infected persons (3). Nevirapine-associated hepatotoxicity has been noted in 8 of 41 healthy volunteers in phase I trials and in 5 of 41 sexual partners of HIV-infected persons who received postexposure prophylaxis that contained nevirapine (4) . Fortunately, in all cases, toxicity resolved after nevirapine was withdrawn.
Because of concern that similar toxicity may have occurred elsewhere and uncertainty that other hepatotoxins may complicate findings from sexual contacts of HIV-infected persons, we evaluated use of nevirapine-containing postexposure prophylaxis after occupational HIV exposures. Three hospitals and one outpatient clinic in the Chicago area used nevirapine-containing regimens as second-line postexposure prophylaxis from October 1999 to September 2000. Among 174 health care workers who received postexposure prophylaxis, 8 received nevirapine-containing regimens and 5 developed severe hepatotoxicity (Table) . A liver biopsy from health care worker 1 showed centrilobular fibrosis and minimal mixed portal infiltrates containing eosinophils. Hepatotoxicity resolved after corticosteroid administration. Health care worker 4, who had fulminant hepatic necrosis, received a liver transplant. At follow-up, none of the health care workers had evidence of HIV infection or hepatitis B or C virus infection.
Nevirapine-associated hepatotoxicity may represent a hypersensitivity reaction also characterized by skin rashes, fevers, and peripheral eosinophilia; rapid onset; and absence of mitochondrial toxicity characteristic of nucleoside analogue toxicity in pathologic specimens. Although nevirapine is potentially useful for postexposure prophylaxis, our findings suggest that immunocompetent persons may be at risk for nevirapine-associated hepatotoxicity that may not be rapidly reversible or may progress to fulminant hepatic necrosis. The use of postexposure prophylaxis regimens containing nevirapine should be discouraged.
